Atopic asthma: the role of allergen-specific immunotherapy



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Bronchial asthma is a heterogeneous disease in terms of the phenotypes, but the majority of patients, both children and adolescents, and adults suffer from IgE-dependent (atopic) asthma. This asthma phenotype most often is associated with allergic rhinitis, which defines systemic therapy for both diseases. The allergen-specific immunotherapy (SIT) meets that approach best of all. SIT is viewed as a treatment not for a specific nosology (rhinitis, asthma or atopic dermatitis), but for an allergen. The epidemiology and the etiology of atopic asthma, role of SIT in treatment of asthma, efficacy, safety, and basic mechanisms are discussed in the article.

Full Text

Restricted Access

About the authors

N M Nenasheva

Russian medical Academy for Postgraduate Education

Email: 1444031@gmail.com

References

  1. GINA,2015 http://www.ginasthma.org.
  2. Strachan D.P. Hay fever, hygiene, and household size. BMJ. 1989, v. 299, p. 1259-1260.
  3. Национальная программа «Бронхиальная астма у детей. Стратегия лечения и профилактика», IV издание. М., 2012, 182 с.
  4. Chuchalin A., Khaltaev N., Antonov N. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. International Journal of COPD. 2014, p. 963-974.
  5. Rackemann F.M. A clinical classification of asthma. Am. J. Med. Sci. 1921, v. 12, p. 802-803.
  6. Johansson S.G., Hourihane J.O., Bousquet J. et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy. 2001, v. 56 (9), p. 813-824.
  7. Ronmark E., Lundback B., Jonsson E. et al. Incidence of asthma in adults - report from the Obstructive Lung Disease in Northern Sweden Study. Allergy. 1997, v. 52, p. 1071-1078.
  8. Pearce N., Pekkanen J., Beasley R. How much asthma is really attributable to atopy? Thorax. 1999, v. 54, p. 268-272/
  9. Чучалин А.Г., Черняк Б.А., Буйнова С.Н., Тяренкова С.В. Распространенность и клинико-аллергологическая характеристика бронхиальной астмы в Восточной Сибири. Пульмонология. 1999, № 1, c. 42-49.
  10. Емельянов А.В., Федосеев Г.Б., Сергеева Г.Р. и соавт. Распространенность бронхиальной астмы и аллергического ринита среди взрослого населения Санкт-Петербурга. Аллергология. 2002, № 2, c. 10-15.
  11. Ненашева Н.М. Клинические фенотипы атопической бронхиальной астмы: диагностика и лечение. Palmarium Academic Publishing. 2012, 319 p.
  12. Boulet L.P., Turcotte H., Laprise C. et al. Comparative degree and type of sensitization to common indoor and outdoor allergens in subjects with allergic rhinitis and/or asthma. Clin. Exp. Allergy. 1997, v. 27, p. 52-59.
  13. Суровенко Т.Н., Железнова Л.В. Акарофауна жилья и ее роль в развитии аллергического воспаления дыхательных путей. Аллергология. 2003, № 1, c. 11-15.
  14. Желтикова Т.М., Овсянникова И.Г., Гервазиева В.Б. Сравнительное изучение популяций клещей домашней пыли и экспозиции клещевых аллергенов (Der I, Der II) в квартирах больных с атопией. Пульмонология. 1994, № 4, c. 19-24.
  15. Vallance G., McSharry C., Wood S., Thomson N.C. House dust mite control measures in the treatment of asthma. Therapeutics and Clinical Risk Management. 2006, v. 2, p. 347-354.
  16. Sporik R., Holgate S., Platts-Mills TA.E. Exposure to house dust mite alergen (Der p I) and the development of asthma in childhood. N. Engl. J. Med. 1990, v. 323, p. 502-507.
  17. Peroni D.G., Boner A.L., Valone G. et al. Effective allergen avoidance at high altitude reduces allergen-induced bronchial hyper-responsiveness. Am. J. Respir. Crit. Care Med. 1994, v. 149, p. 1442-1446.
  18. Zureik M., Neukirch C., Leynaert B. et al. Sensitisation to airborne moulds and severity of asthma: cross sectional study from European Community respiratory health survey. BMJ. 2002, v. 325, p. 411-419.
  19. Sears M.R., Greene J.M., Willan A.R. et al. A longitudinal, population-based, cohort study of childhood asthma followed to adulthood. N. Engl. J. Med. 2003, v. 349, p. 1414-1422.
  20. Takkouche B., Gonzalez-Barcala F.J., Etminan M., Fitzgerald M. Exposure to furry pets and the risk of asthma and allergic rhinitis: a meta-analysis. Allergy. 2008, v. 63, p. 857-864.
  21. Lodge C.J., Allen K., Lowe A.J. et al. Perinatal Cat and Dog Exposure and the Risk of Asthma and Allergy in the Urban Environment: A Systematic Review of Longitudinal Studies. Clinical and Developmental Immunology. 2012, p. 10.
  22. Hesselmar B., Aberg B., Eriksson B. et al. High-dose exposure to cat is associated with clinical tolerance - a modified Th2 immune response? Clin. Exp. Allergy. 2003, v. 33, p. 1681-1685.
  23. Platts-Mills T., Vaughan J., Squillace S. et al. Sensitisation, asthma, and a modified th2 response in children exposed to cat allergen: A population-based cross-sectional study. Lancet. 2001, v. 357, p. 752-756.
  24. Berge M., Munir A.K., Dreborg S. Concentrations of cat (Fel d1), dog (Can f1) and mite (Der p1) allergens in the clothing and school environment of Swedish schoolchildren with and without pets at home. Pediatr. Allergy Immunol. 1998, v. 9, p. 25-30.
  25. Schappi G.F., Taylor P.E., Staff I.A. et al. Immunologic significance of respirable atmospheric starch granules containing major birch allergen Bet v 1. Allergy. 1999, v. 54, p. 478-483.
  26. Grote M., Vrtala S., Niederberger V. et al. Expulsion of allergen-containing materials from hydrated rye grass (Lolium perenne) pollen revealed by using immunogold field emission scanning and transmission electron microscopy. J. Allergy Clin. Immunol. 2000, v. 105, p. 1140-1145.
  27. Taylor P.E., Flagan R.C., Miguel A.G. et al. Birch pollen rupture and the release of aerosols of respirable allergens. Clin. Exp. Allergy. 2004, v. 34, p. 1591-1596.
  28. Wark P.A., Simpson J., Hensley M.J., Gibson P.G. Airway inflammation in thunderstorm asthma. Clin. Exp. Allergy. 2002, v. 32, p. 1750-1756.
  29. Bacsi A., Choudhury B.K., Dharajiya N. et al. Subpollen particles: Carriers of allergenic proteins and oxidases. The Journal of allergy and clinical immunology. 2006, v. 118, p. 844-850.
  30. Bousquet J., Khaltaev N., Cruz A.A. et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen) Allergy. 2008, v. 63, p. 8-160.
  31. Spergel J.M. Atopic march: link to upper airways. Curr. Opin. Allergy Clin. Immunol. 2005, v. 5, p. 17-21.
  32. Braunstahl G.J., Hellings P.W. Nasobronchial interaction mechanisms in allergic airways disease. Curr. Opin. Otolaryngol. Head. Neck. Surg. 2006, v. 14, p. 176-182.
  33. Abramson M.J., Puy R.M., Weiner J.M. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am. J. Respir. Crit. Care Med. 1995, v. 151, p. 969-974.
  34. Abramson M.J., Puy R.M., Weiner J.M. Allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2003, v. 4, CD001186.
  35. Abramson M.J., Puy R.M., Winer J.M. Injection allergen immunotherapy for asthma. Cochrane Database Syst. Rev. 2010, v. 8: CD001186.
  36. Erekosima N., Suarez-Cuervo C., Ramanathan M. et al. Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma: A systematic review. Laryngoscope. 2013, v. 5, p. 10.
  37. Calamita Z., Saconato H., Bronhara Pela A., Atallah A.N. Efficacy of Sublingual immunotherapy in asthma. Systematic review of randomized clinical trials. Allergy. 2006, v. 61, p. 1162-1172.
  38. Penagos M., Passalacqua G., Compalati E. et al. Meta-analysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest. 2008, v. 133, p. 599-609.
  39. Compalati E., Passalacqua G., Bonini M., Canonica G.W. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy. 2009, v. 64, p. 1570-1579.
  40. Lianqin Tao, Baoyu Shi, Guochao Shi, Huanying Wan. Efficacy of sublingual immunotherapy for allergic asthma: retrospective meta-analysis of randomized, double-blind and placebo-controlled trials. The Clinical Respiratory Journal. 2014, v. 8, p. 192-205.
  41. Canonica G.W, Baena Cagnani C.E., Bousquet J. et al. Recommendations for standardized clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of the World Allergy Organization (WAO) taskforce. Allergy. 2007, v. 62, p. 317-324.
  42. Frew A.J., Powell R.J., Corrigan C.J., Durham S.R. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 2007, v. 117, p. 319-325.
  43. Dahl R., Kapp A., Colombo G. et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 2006, v. 118, p. 434-440.
  44. Didier A., Malling H.J., Worn M. et al. Optimal dose, efficacy and safety of once-daily sublingual immunotherapy with 5-grass pollen tablet for seasonal allergic rhinitis. J. Allergy Clin. Immunol. 2007, v. 120, p. 1338-1345.
  45. Cox L., Calderón M., Pfaar O. Subcutaneous allergen immunotherapy for allergic disease: examining efficacy, safety and cost-effectiveness of current and novel formulations. Immunotherapy. 2012, v. 4, p. 601-616.
  46. Черняк Б.А., Сукманская Е.О., Воржева И.И. Результаты аллерген-специфической иммунотерапии больных бронхиальной астмой. сочетающейся с аллергическим ринитом. Рос. Аллергол. Журн. 2004, № 1, c. 22-28.
  47. Blumberga G., Groes L., Haugaard L., Dahl R. Steroid-sparing effect of subcutaneous SQ-standardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics. Allergy. 2006, v. 61, p. 843-848.
  48. Zielen S., Kardos P., Madonini E. Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial. J. Allergy Clin. Immunol. 2010, v. 126, p. 942-949.
  49. Mosbech H., Deckelmann R., de Blay F. et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J. Allergy Clin. Immunol. 2014, v. 134, p. 568-575.
  50. Wang L., Yin J., Fadel R. et al. House dust mite sublingual immunotherapy is safe and appears to be effective in moderate, persistent asthma. Allergy. 2014, v. 69, p. 1181-1188.
  51. Mosbech H., Deckelmann R., de Blay F. et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J. Allergy Clin. Immunol. 2014, v. 134, p. 568-575.
  52. Marogna M., Spadolini I., Massolo A. et al. and Passalacqua G. Long-term comparison of sublingual immunotherapy vs inhaled budesonide in patients with mild persistent asthma due to grass pollen. Ann. Allergy Asthma Immunol. 2014, v. 102, p. 69-75.
  53. Karagiannis E., Shah-Hosseini K., Hadler M., Ralph Mosges. Asthmatic children and adolescents treated in daily medical practice - results from a 2-year sublingual allergen immunotherapy (AIT) study with grass pollen tablets. Clinical and Translational Allergy. 2014, v. 4, p. 140.
  54. Jacobsen L., Niggemann B., Dreborg S. et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy.
  55. Novembre E., Galli E., Landi F. et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 2004, v. 114, p. 851-857.
  56. Shaikh W.A. Immunotherapy vs inhaled budesonide in bronchial asthma: an open, parallel, comparative trial. Clin. Exp. Allergy. 1997, v. 27, p. 1279-1284.
  57. Marogna M., Spadolini I., Massolo A. et al. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J. Allergy Clin. Immunol. 2010, v. 126, p. 969-975.
  58. Didier A., Malling H.J., Worm M. et al. Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score. Clinical and Translational Allergy. 2015, v. 5, p. 12.
  59. Des Roches A., Paradis L., Menardo J.L. et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J. Allergy Clin. Immunol. 1997, v. 99, p. 450-453.
  60. Pajno G.B., Barberio G., De Luca F. et al. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin. Exp. Allergy. 2001, v. 31, p. 1392-1397.
  61. Purello-D’Ambrosio F., Gangemi S., Merendino R.A. et al. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin. Exp. Allergy. 2001, v. 31, p. 1295-1302.
  62. Inal A., Altintas D.U., Yilmaz M. et al. Prevention of new sensitizations by specific immunotherapy in children with rhinitis and/or asthma monosensitized to house dust mite. J. Investig. Allergol. Clin. Immunol. 2007, v. 17, p. 85-91.
  63. Marogna M., Tomassetti D., Bernasconi A. et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann. Allergy Asthma Immunol. 2008, v. 101, p. 206-211.
  64. Durham S.R., Emminger W., Kapp A. et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J. Allergy Clin. Immunol. 2010, v. 125, p. 131-138.
  65. Marogna M., Spadolini I., Massolo A. et al. Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more. Allergy. 2004, v. 59, p. 1205-1210.
  66. Durham S.R., Walker S.M., Varga E.M. et al. Long-term clinical efficacy of grass-pollen immunotherapy. N. Engl. J. Med. 1999, v. 341, p. 468-475.
  67. Varney V.A., Hamid Q.A., Gaga M. et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J. Clin. Invest. 1993, v. 92, p. 644-651.
  68. Benjaponpitak S., Oro A., Maguire P et al. The kinetics of change in cytokine production by CD4 T-cells during conventional allergen immunotherapy. J. Allergy Clin. Immunol. 1999, v. 103, p. 468-475.
  69. Nish W.A., Charlesworth E.N., Davis TL. et al. The effect of immunotherapy on the cutaneous late phase response to antigen. J. Allergy Clin. Immunol. 1994, v. 93, p. 484-493.
  70. Shamji M.H., Durham S.R. Mechanisms of immunotherapy to aeroallergens. Clin. Exp. Allergy. 2011, v. 41, p. 1235-1246.
  71. Wachholz P.A., Nouri-Aria K.T., Wilson D.R. et al. Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios. Immunology. 2002, v. 105, p. 56-62.
  72. Scadding G., Durham S. Mechanisms of sublingual immunotherapy. J. Asthma. 2009, v. 46, p. 322-334.
  73. Jutel M., Akdis M., Budak F. et al. IL-10 and TGFp cooperate in the regulatory T-cell response to mucosal allergens in nor mal immunity and specific immunotherapy. Eur. J. Immunol. 2003, v. 33, p. 1205-1214.
  74. Faith A., Richards D.F., Verhoef A. et al. Impaired secretion of interleukin-4 and interleukin-13 by allergen-specific T-cells correlates with defective nuclear expression of NF-AT2 and jun B: relevance to immunotherapy. Clin. Exp. Allergy. 2003, v. 3, p. 1209-1215.
  75. Durham S.R., Ying S., Varney V.A. et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T-lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J. Allergy Clin. Immunol. 1996, v. 97, p. 1356-1365.
  76. Francis J.N., James L.K., Paraskevopoulos G. et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J. Allergy Clin. Immunol. 2008, v. 121, p. 1120-1125.
  77. Gorelik L., Constant S., Flavell R.A. Mechanism of transforming growth factor beta-induced inhibition of T-helper type 1 differentiation. J. Exp. Med. 2002, v. 195, p. 1499-505.
  78. Gorelik L., Fields P.E., Flavell R.A. Cutting edge: TGFp inhibits Th type 2 development through inhibition of GATA-3 expression. J. Immunol. 2000, v. 165, p. 4773-4777.
  79. Pilette C., Nouri-Aria K.T, Jacobson M.R.et al. Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGFp expression. J. Immunol. 2007, v. 178, p. 4658-4666.
  80. Pree I., Shamji M.H., Kimber I. et al. Inhibition of CD23-de-pendent facilitated allergen binding to B-cells following vaccination with genetically modified hypoallergenic Bet v 1 molecules. Clin. Exp. Allergy. 2010, v. 40, p. 346-352.
  81. Scadding G.W., Shamji M.H., Jacobson M.R. et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B-cells. Clin. Exp. Allergy. 2010, v. 40, p. 598-606.
  82. Novak N., Haberstok J., Bieber T., Allam J.P. The immune privilege of the oral mucosa. Trends. Mol. Med. 2008, v. 14, p. 191-198.
  83. Marcucci F., Incorvaia C., Sensi L. et al. Lack of inflammatory cells in the oral mucosa of subjects undergoing sublingual immunotherapy. Int. J. Immunolpathol. Pharmacol. 2008, v. 21, p. 609-614.
  84. Bagnasco M., Altrinetti V., Pesce G. et al. Pharmacokinetics of Der p 2 allergen and derived monomeric allergoid in allergic volunteers. Int. Arch. Allergy Immunol. 2005, v. 138, p. 197-202.
  85. Calderon M.A., Simons F.E.R., Malling H.J. et al. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy. 2012, v. 67, p. 302-311.
  86. Bernstein D.I., Epstein T, Murphy-Berendts K., Liss G.M. Surveillance of systemic reactions to subcutaneous immunotherapy injections: year 1 outcomes of the ACAAI and AAAAI collaborative study. Ann. Allergy Asthma Immunol. 2010, v. 104, p. 530-535.
  87. Passalacqua G., Durham S.R. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J. Allergy Clin. Immunol. 2007, v. 119, p. 881-891.
  88. Corrigan C.J., Kettner J., Doemer C. et al. Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. Allergy. 2005, v. 60, p. 801-807.
  89. Jutel M., Jaeger L., Suck R. et al. Allergen-specific immunotherapy with recombinant grass pollen allergens. J. Allergy Clin. Immunol. 2005, v. 116, p. 608-613.
  90. Schiappoli M., Ridolo E., Senna G. et al. A prospective Italian survey on the safety of subcutaneous immunotherapy for respiratory allergy. Clin. Exp. Allergy. 2009, v. 39, p. 1569-1574.
  91. российский Аллергологический ^Журнал № 6-2015 Атопическая бронхиальная астма: роль аллерген-специфической иммунотерапии
  92. Rank M.A., Oslie C.L., Krogman J.L. et al. Allergen immunotherapy safety: characterizing systemic reactions and identifying risk factors. Allergy Asthma Proc. 2008, v. 29, p. 400-405.
  93. Jutel M., Agache I., Bonin S. et al. International consensus on allergy immunotherapy. J. Allergy Clin. Immunol. 2015, v. 136, p. 556-568.
  94. Cox L.S., Larenas-Linnemann D., Nolte H. et al. Sublingual immunotherapy: a comprehensive review. J. Allergy Clin. Immunol. 2006, v. 117, p. 1021-1035.
  95. Compalati E., Braido F., Canonica G.W. Sublingual Immunotherapy: Recent Advances. Allergol. Int. 2013, v. 62, p. 415-423.
  96. Alvarez-Cuesta E., Bousquet J., Canonica G.W et al. Standards for practical allergen-specific immunotherapy. Allergy. 2006, v. 61, p. 1-20.
  97. Burastero S., Regarding Gidaro G.B., Marcucci F. et al. The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin. Exp. Allergy. 2005, v. 35, p. 565-571.
  98. De Groot H., Bijil A. Anaphilactic reaction after the first dose of sublingual immunotherapy with grass pollen tablets. Allergy. 2009, v. 64, p. 963-964.
  99. Dahl R., Stender A., Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhino-conjunctivitis. Allergy. 2006, v. 61, p. 185-190.
  100. Malling H.J., Montagut A., Melac M. et al. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis. Clin. Exp. Allergy. 2009, v. 39, p. 387-339.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 2015



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies